Literature DB >> 24668619

Isolated terminal limb reduction defects: extending the clinical spectrum of Adams-Oliver syndrome and ARHGAP31 mutations.

Mala Isrie1, Wim Wuyts, Hilde Van Esch, Koenraad Devriendt.   

Abstract

Adams-Oliver syndrome (AOS; OMIM 100300) typically comprises a combination of congenital scalp defects and terminal transverse limb defects. Recently, mutations in ARHGAP31 and RBPJ have been found causing autosomal dominant forms of AOS. We describe a four-generation pedigree with isolated terminal limb defects and a truncating mutation in ARHGAP31. This finding underscores the relevance of sequencing ARHGAP31 in similar cases of isolated limb defects, irrespective of the presence of a complete AOS phenotype. We also highlight the variability of clinical features among mutation carriers, ranging from severe reduction defects to mild as well as clinically unaffected cases suggesting reduced penetrance.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  ARHGAP31; Adams-Oliver; autosomal dominant; limb reduction; transverse terminal limb defect

Mesh:

Substances:

Year:  2014        PMID: 24668619     DOI: 10.1002/ajmg.a.36486

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  7 in total

1.  Haploinsufficiency of the NOTCH1 Receptor as a Cause of Adams-Oliver Syndrome With Variable Cardiac Anomalies.

Authors:  Rajiv D Machado; Richard C Trembath; Laura Southgate; Maja Sukalo; Anastasios S V Karountzos; Edward J Taylor; Claire S Collinson; Deborah Ruddy; Katie M Snape; Bruno Dallapiccola; John L Tolmie; Shelagh Joss; Francesco Brancati; M Cristina Digilio; Luitgard M Graul-Neumann; Leonardo Salviati; Wiltrud Coerdt; Emmanuel Jacquemin; Wim Wuyts; Martin Zenker
Journal:  Circ Cardiovasc Genet       Date:  2015-05-11

2.  CdGAP/ARHGAP31, a Cdc42/Rac1 GTPase regulator, is critical for vascular development and VEGF-mediated angiogenesis.

Authors:  Christine Caron; Jonathan DeGeer; Patrick Fournier; Philippe M Duquette; Vilayphone Luangrath; Hidetaka Ishii; Fereshteh Karimzadeh; Nathalie Lamarche-Vane; Isabelle Royal
Journal:  Sci Rep       Date:  2016-06-07       Impact factor: 4.379

3.  The scaffold protein Ajuba suppresses CdGAP activity in epithelia to maintain stable cell-cell contacts.

Authors:  J J McCormack; S Bruche; A B D Ouadda; H Ishii; H Lu; A Garcia-Cattaneo; C Chávez-Olórtegui; N Lamarche-Vane; V M M Braga
Journal:  Sci Rep       Date:  2017-08-23       Impact factor: 4.379

4.  The Cdc42/Rac1 regulator CdGAP is a novel E-cadherin transcriptional co-repressor with Zeb2 in breast cancer.

Authors:  Y He; J J Northey; A Pelletier; Z Kos; L Meunier; B Haibe-Kains; A-M Mes-Masson; J-F Côté; P M Siegel; N Lamarche-Vane
Journal:  Oncogene       Date:  2017-01-30       Impact factor: 9.867

5.  Elucidating the genetic architecture of Adams-Oliver syndrome in a large European cohort.

Authors:  Josephina A N Meester; Maja Sukalo; Kim C Schröder; Denny Schanze; Gareth Baynam; Guntram Borck; Nuria C Bramswig; Duygu Duman; Brigitte Gilbert-Dussardier; Muriel Holder-Espinasse; Peter Itin; Diana S Johnson; Shelagh Joss; Hannele Koillinen; Fiona McKenzie; Jenny Morton; Heike Nelle; Willie Reardon; Claudia Roll; Mustafa A Salih; Ravi Savarirayan; Ingrid Scurr; Miranda Splitt; Elizabeth Thompson; Hannah Titheradge; Colm P Travers; Lionel Van Maldergem; Margo Whiteford; Dagmar Wieczorek; Geert Vandeweyer; Richard Trembath; Lut Van Laer; Bart L Loeys; Martin Zenker; Laura Southgate; Wim Wuyts
Journal:  Hum Mutat       Date:  2018-07-04       Impact factor: 4.878

6.  Synergistic effects of rare variants of ARHGAP31 and FBLN1 in vitro in terminal transverse limb defects.

Authors:  Hong Tian; Fan Chu; Yingjie Li; Mengmeng Xu; Wenjiao Li; Chuanzhou Li
Journal:  Front Genet       Date:  2022-09-13       Impact factor: 4.772

7.  CdGAP/ARHGAP31 is regulated by RSK phosphorylation and binding to 14-3-3β adaptor protein.

Authors:  Ali Ben Djoudi Ouadda; Yi He; Viviane Calabrese; Hidetaka Ishii; Rony Chidiac; Jean-Philippe Gratton; Philippe P Roux; Nathalie Lamarche-Vane
Journal:  Oncotarget       Date:  2018-01-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.